FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2506843278> ?p ?o ?g. }

• W2506843278 abstract "Sodium-glucose co-transporter-2 (SGLT2) inhibitors are new oral antidiabetic drugs that reduce hyperglycemia by promoting urinary glucose excretion. Glycosuria produced by SGLT2 inhibitors is associated with weight loss, mainly due to reduced fat volume. We investigated the effects of empagliflozin (selective SGLT2 inhibitor) and linagliptin (DPP-4 inhibitor) on steatohepatitis and fibrosis in a mouse model of non-alcoholic steatohepatitis (NASH) with diabetes.A novel NASH model was generated by administration of streptozotocin to C57BL/6J mice at 2 days old, with a high-fat diet from 4 weeks. NASH mice aged 6 weeks were divided into four groups of 6 animals: vehicle, linagliptin (10 mg/kg), empagliflozin (10 mg/kg), and linagliptin + empagliflozin. The histological non-alcoholic fatty liver disease activity score was significantly lower in the empagliflozin and linagliptin + empagliflozin groups than in the vehicle or linagliptin groups. Hepatic expression of inflammatory genes (tumor necrosis factor-α, interleukin-6, and monocyte chemoattractant protein-1) was decreased in the empagliflozin and linagliptin + empagliflozin groups compared with the vehicle group. The collagen deposition with Sirius red staining was significantly reduced in the linagliptin + empagliflozin group compared with the linagliptin or the empagliflozin group. Immunohistochemistry showed that expression of α-smooth muscle actin, a marker of myofibroblasts (fibrosis), was reduced in the linagliptin + empagliflozin group compared with the vehicle group, as was expression of type 1 and 3 collagen mRNA. Linagliptin + empagliflozin decreased expression of mRNAs for genes related to fatty acid synthesis, but did not increase mRNAs for β-oxidation-related genes.While empagliflozin alone attenuates development of NASH showing anti-steatotic and anti-inflammatory effects, combined administration of empagliflozin and linagliptin can synergistically ameliorates NASH with stronger anti-fibrotic effects." @default.
• W2506843278 created "2016-08-23" @default.
• W2506843278 creator A5002804119 @default.
• W2506843278 creator A5008322865 @default.
• W2506843278 creator A5025316757 @default.
• W2506843278 creator A5038865449 @default.
• W2506843278 creator A5066098744 @default.
• W2506843278 creator A5070910498 @default.
• W2506843278 date "2016-07-26" @default.
• W2506843278 modified "2023-10-14" @default.
• W2506843278 title "Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes" @default.
• W2506843278 cites W1499407397 @default.
• W2506843278 cites W1602023824 @default.
• W2506843278 cites W1988777910 @default.
• W2506843278 cites W1990411608 @default.
• W2506843278 cites W1999374351 @default.
• W2506843278 cites W2002034811 @default.
• W2506843278 cites W2006095657 @default.
• W2506843278 cites W2010055261 @default.
• W2506843278 cites W2012425798 @default.
• W2506843278 cites W2012528744 @default.
• W2506843278 cites W2020537103 @default.
• W2506843278 cites W2026450587 @default.
• W2506843278 cites W2040109162 @default.
• W2506843278 cites W2047257800 @default.
• W2506843278 cites W2054677013 @default.
• W2506843278 cites W2055473817 @default.
• W2506843278 cites W2059251195 @default.
• W2506843278 cites W2067740038 @default.
• W2506843278 cites W2069711307 @default.
• W2506843278 cites W2070029794 @default.
• W2506843278 cites W2080999576 @default.
• W2506843278 cites W2095574383 @default.
• W2506843278 cites W2102849202 @default.
• W2506843278 cites W2134855422 @default.
• W2506843278 cites W2151345870 @default.
• W2506843278 cites W2156116850 @default.
• W2506843278 cites W2157338541 @default.
• W2506843278 cites W2167245776 @default.
• W2506843278 cites W2173615285 @default.
• W2506843278 cites W2176471470 @default.
• W2506843278 cites W2224883440 @default.
• W2506843278 cites W2302367542 @default.
• W2506843278 doi "https://doi.org/10.1186/s13098-016-0169-x" @default.
• W2506843278 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4960737" @default.
• W2506843278 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27462372" @default.
• W2506843278 hasPublicationYear "2016" @default.
• W2506843278 type Work @default.
• W2506843278 sameAs 2506843278 @default.
• W2506843278 citedByCount "142" @default.
• W2506843278 countsByYear W25068432782016 @default.
• W2506843278 countsByYear W25068432782017 @default.
• W2506843278 countsByYear W25068432782018 @default.
• W2506843278 countsByYear W25068432782019 @default.
• W2506843278 countsByYear W25068432782020 @default.
• W2506843278 countsByYear W25068432782021 @default.
• W2506843278 countsByYear W25068432782022 @default.
• W2506843278 countsByYear W25068432782023 @default.
• W2506843278 crossrefType "journal-article" @default.
• W2506843278 hasAuthorship W2506843278A5002804119 @default.
• W2506843278 hasAuthorship W2506843278A5008322865 @default.
• W2506843278 hasAuthorship W2506843278A5025316757 @default.
• W2506843278 hasAuthorship W2506843278A5038865449 @default.
• W2506843278 hasAuthorship W2506843278A5066098744 @default.
• W2506843278 hasAuthorship W2506843278A5070910498 @default.
• W2506843278 hasBestOaLocation W25068432781 @default.
• W2506843278 hasConcept C126322002 @default.
• W2506843278 hasConcept C134018914 @default.
• W2506843278 hasConcept C2775887513 @default.
• W2506843278 hasConcept C2777180221 @default.
• W2506843278 hasConcept C2778763485 @default.
• W2506843278 hasConcept C2778772119 @default.
• W2506843278 hasConcept C2779134260 @default.
• W2506843278 hasConcept C2779478299 @default.
• W2506843278 hasConcept C2779770810 @default.
• W2506843278 hasConcept C2780031085 @default.
• W2506843278 hasConcept C2780559512 @default.
• W2506843278 hasConcept C555293320 @default.
• W2506843278 hasConcept C71924100 @default.
• W2506843278 hasConcept C98274493 @default.
• W2506843278 hasConceptScore W2506843278C126322002 @default.
• W2506843278 hasConceptScore W2506843278C134018914 @default.
• W2506843278 hasConceptScore W2506843278C2775887513 @default.
• W2506843278 hasConceptScore W2506843278C2777180221 @default.
• W2506843278 hasConceptScore W2506843278C2778763485 @default.
• W2506843278 hasConceptScore W2506843278C2778772119 @default.
• W2506843278 hasConceptScore W2506843278C2779134260 @default.
• W2506843278 hasConceptScore W2506843278C2779478299 @default.
• W2506843278 hasConceptScore W2506843278C2779770810 @default.
• W2506843278 hasConceptScore W2506843278C2780031085 @default.
• W2506843278 hasConceptScore W2506843278C2780559512 @default.
• W2506843278 hasConceptScore W2506843278C555293320 @default.
• W2506843278 hasConceptScore W2506843278C71924100 @default.
• W2506843278 hasConceptScore W2506843278C98274493 @default.
• W2506843278 hasIssue "1" @default.
• W2506843278 hasLocation W25068432781 @default.
• W2506843278 hasLocation W25068432782 @default.
• W2506843278 hasLocation W25068432783 @default.
• W2506843278 hasLocation W25068432784 @default.
• W2506843278 hasOpenAccess W2506843278 @default.

• next